Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNC therapy for spinal cord injury
NCT02027246Phase 1Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Dec 2008
- Primary completion
- Aug 2012
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous bone marrow-derived mononuclear cell in spinal cord injury (SCI), sponsored by NeuroGen Brain & Spine Institute. Primary endpoint: Change in clinical symptoms at 6 months. Planned start Dec 2008; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02027246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027246.